Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.

Nat Med · 2022 · PMC9499854 · PMID 35995953

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a weak trendno p-value reported

OS showed only a weak trend with cutoffs above 13.6 mutations per megabase using F1L CDx.

also in 1,404 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.